Latest news with #NASH
Time of India
23-05-2025
- Health
- Time of India
From belly fat to fatty liver: When weight gain speaks louder than you think
Although many people believe that gaining weight is an inevitable consequence of modern life, there might be more going on here than meets the eye as fat accumulates around the abdomen. Tired of too many ads? go ad free now This seeming alteration can be an indicator to an underlying metabolic disorder, which might be able to prolong and covertly impact vital metabolic organs like the liver. Among all of these issues, non-alcoholic fatty liver disease (NAFLD) is becoming more and more prominent as a condition with major health implications and a close connection to abdominal obesity. When fat builds up in the liver in people who consume little or no alcohol, it can lead to nonalcoholic fatty liver disease (NAFLD). It currently affects millions of people of all ages and is thought to be the leading cause of chronic liver disease worldwide. Central obesity, insulin resistance, type 2 diabetes, and hyperlipidemia—all components of the metabolic syndrome—are closely linked to the disorder. Visceral, or abdominal, fat has biological activity. It releases hormones and inflammatory substances that disrupt the liver's and other organs' regular functions. A series of metabolic disturbances can happen as the liver starts to retain fat in excess of what is typical. Steatosis, also known as fatty liver, is the accumulation of fat over time that can cause non-alcoholic steatohepatitis (NASH), which is inflammation and damage to the liver cells for wear. It can then lead to cirrhosis, fibrosis, and even liver cancer. NAFLD can be a silent killer because it may not show any symptoms until it is well-established. Tired of too many ads? go ad free now A lot of cases are discovered by chance when we're doing normal health checks or looking into other issues. Elevated liver enzymes on a blood test, fatty infiltration on ultrasonography, or a FibroScan measurement of liver stiffness might all raise suspicions of NAFLD. A liver biopsy may occasionally be required to confirm the diagnosis and assess the degree of liver damage. Managing fatty liver disease focuses mainly on treating the causes. Importantly, the management of fatty liver disease comprises lifestyle changes such as: Weight loss: Loss of 5–10% body weight can improve liver fat and inflammation. Weight loss should be gradual, because rapid weight loss can worsen liver function. Dietary modifications: It is important that the diet is nutrient-dense and limits saturated fats, added sugar, and refined carbohydrates. The Mediterranean diet is nutrient-dense and consists of food such as vegetables, fruit, whole grain, lean protein, and healthy fats. This eating habits has shown great potential relevance to resolving fatty liver disease. Regular exercise: At least 150 minutes of moderate-intensity physical activity can improve insulin sensitivity and decrease liver fat independent of weight loss. Medical Management: No medication has been authorized expressly to treat non-alcoholic fatty liver disease. Guidelines are implemented for treating diabetes, high blood pressure, and high cholesterol in relation to fatty liver disease. For some patients, vitamin E and specific insulin-sensitizing medications may be taken into consideration. Patients could require more intensive treatment if they have severe liver damage. A liver transplant treatment might be necessary for patients with cirrhosis. Important preventive actions include keeping an eye on waist circumference and preserving a healthy body composition. A belly fad should not be written off as harmless; rather, it is a biochemical indication that the body's internal equilibrium might be in risk. Early liver damage can be reversed and potential long-term problems could be avoided with the combination of timely medical treatment and consistent lifestyle changes. Dr. Mangesh Keshavrao Borkar, Consultant - Medical Gastroenterologist, Manipal Hospitals, Kharadi, Pune
New European
20-05-2025
- Politics
- New European
Alastair Campbell's diary: Labour must reverse the winter fuel allowance cuts
'Despite all the damage Brexit has done, despite all the lies told and the promises broken by the charlatans who led the fight for it, despite all the bullshit fake patriotic coverage in the right wing rags over decades, the broadcasters continue to take their lead from the same people and papers who got us into the mess in the first place. The real surrender has been to their lies and propaganda. We will only properly fix the mess if we admit the scale of it and start to put those who led the campaign for it under the kind of scrutiny and pressure from which the media and mainstream political class has inexplicably spared them.' I'm pleased that both sides have shared a determination to bring down some of the trade barriers that NASH (National Act of Self-Harm 23/06/16) erected. But while we're thinking big and bold, I think the time may be ripe for a big, bold swallow, and an announcement of a reversal of the winter fuel allowance cuts. Not for people like me – yes, yes, I know… you can't believe I am a pensioner – because I think people don't object to ending the universal nature of the payment. But of all the things that the Labour government has done, this is the one that has done the most political damage, and it continues to do so. Some U-turns can get you back on the right road. A busy week on the podcast interview front… Jacinda Ardern, Ed Miliband, and Arab Barghouthi. I'm guessing you've all recognised the first of those two names – Jacinda the former New Zealand prime minister, who is about to publish her highly emotional autobiography (spoiler alert, I really like it, but I'm biased, because I really like her); and Ed the former Labour minister and former Labour leader who lost an election but stayed around in frontline politics and is now the Cabinet minister charged with stopping the planet burning to death. The third name, I suspect, may be less familiar to you. Arab Barghouti knows that we interviewed him not because of who he is, but because of who his father is. So why not interview the father instead, you wonder? The answer is that Marwan Barghouthi has been in an Israeli jail for more than 20 years, and just as it's impossible for us to get into Gaza right now, ditto the jail where our interviewee's dad has spent much of his time in solitary confinement. He too may not be familiar to all of our readers. But in the Middle East Marwan Barghouthi is a household name, to many a hero, and to some – including Israeli politicians more moderate than those driving the current government – the man who could and should be the leader of the Palestinian people. As the horror and brutality of the Hamas attacks of October 7 unfolded, Rory Stewart and I decided that we should use the Rest Is Politics platform to try to explain the history of the conflict and the political complexities, and seek to be fair and balanced in our approach to all sides. We got plenty of plaudits for that effort, Rory's explainer of the history getting shared and viewed many millions of times, but also lots of flak; supporters of Israel sometimes felt we were apologists for terrorists, supporters of the Palestinians were more likely to suggest we were too soft on the Israeli government. But what started out as a fight between Israel and Hamas is now a fight by the government of Israel against the Palestinian people. What qualifies as genocide is a question for international law. However, that the far-right extremists in the Israeli government, led by Itamar Ben Gvir and Bezalel Smotrich, are acting with genocidal intent, can hardly be disputed; that intent is evident pretty much every time they open their mouths. One reason diplomats and politicians are attracted to the notion of President Marwan Barghouti is his lifelong commitment to a two-state solution which recognises Israel – he is fluent in Hebrew, which he learned in prison, and has built good relations with many Israeli politicians in the past – and his rejection of the taking of civilian life in the fight for the Palestinian cause. I strongly recommend you listen to Mr Barghouti Junior – the interview is out on our LEADING channel now – not just for the family story, but for his account of what life is really like for Palestinians in Gaza and the West Bank, and the suffering being deliberately inflicted upon them. I also urge the Israeli government media team to listen too, and understand that sometimes you can get your points across better by speaking softly, clearly and calmly, rather than just hammering pre-prepared talking points, and attacking the questioner when you don't like the question. Amid the bling, and the bung of a free Boeing 747, and the billion-dollar business deals, there was a lot of substance in Donald Trump's tour of the Gulf. That impression was perhaps reinforced by my new Trump-consumption tactic – I read rather than watch his speeches. The stomach churns a little less when you are not confronted by the whole monstrous picture. Strip away the usual BS and bluster, and his big speech in Riyadh was interesting, well-argued, and with a lot of food for thought. The historic stand-out moment from the trip, à mon avis, was his meeting with President Ahmed al-Sharaa, and his announcement that sanctions were to be lifted on Syria. Just three months ago (with apologies for another podcast plug, but it is relevant), we interviewed al-Sharaa, and though it was clear getting sanctions lifted was his big goal, he had little expectation that it would happen any time soon. And here we are, it's done, cue dancing in the streets of Damascus. The same people who have been giving me and Rory Stewart grief for being too hard (sic) on Israel were livid that we travelled to Syria to talk to al-Sharaa. Yet Trump lifts sanctions, praises to the skies a man who not long ago had a 'Most Wanted' multi-million bounty on his head, tells him how strong and handsome he is to boot, and largely pulls it off without opprobrium. Trump is nothing if not unpredictable, if I may mangle a mouthful of negatives. This particular piece of unpredictability strikes me as a risk worth taking. I'm not a big fan of awards ceremonies – black tie, usually too long, often cringe acceptance speeches – but I always make an exception for the Sport Industry Awards. I have been a judge, which gave me a great insight into the scope, scale – and impact – of the industry, and all it contributes to the UK. At this year's awards I presented the Integrity and Impact Award to a wonderful man named Mel Young, a homelessness campaigner. In his acceptance speech, Mel, a soft-spoken Scot, summed up his approach to life by saying that just because you can't do everything, you mustn't do nothing… you do something. His something was founding the Homeless World Cup in 2003, since when more than 100,000 homeless youngsters, across 74 countries and 450 cities, have been given the chance to take part in an international sports tournament. That of itself does not put a roof over their heads. But it gives them a chance, and plenty have seized it. The Lifetime Achievement Award went to boxing promoter Frank Warren and the Outstanding Contribution Award to cyclist Sarah Storey. She has won 19 Paralympic gold medals, and if she stays fit Los Angeles 2028 will be her TENTH Paralympics. Given the general British hopelessness at learning foreign languages, it was good to hear her explain how she won that last medal in Paris. She was up against a 'young French wonderkid,' and as they chased each other around the track, she could hear her rival's coach bellowing out tactical instructions. Doubtless the Frenchman assumed that Sarah was just your average Brit who didn't bother with other languages, because English is King. Little did he know!
Globe and Mail
19-05-2025
- Business
- Globe and Mail
NASH Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501: Terns Pharmaceuticals TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
New European
19-05-2025
- Politics
- New European
Alastair Campbell's diary: This UK-EU reset must be just the start
'Despite all the damage Brexit has done, despite all the lies told and the promises broken by the charlatans who led the fight for it, despite all the bullshit fake patriotic coverage in the right wing rags over decades, the broadcasters continue to take their lead from the same people and papers who got us into the mess in the first place. The real surrender has been to their lies and propaganda. We will only properly fix the mess if we admit the scale of it and start to put those who led the campaign for it under the kind of scrutiny and pressure from which the media and mainstream political class has inexplicably spared them.' I'm pleased that both sides have shared a determination to bring down some of the trade barriers that NASH (National Act of Self-Harm 23/06/16) erected. But while we're thinking big and bold, I think the time may be ripe for a big, bold swallow, and an announcement of a reversal of the winter fuel allowance cuts. Not for people like me – yes, yes, I know… you can't believe I am a pensioner – because I think people don't object to ending the universal nature of the payment. But of all the things that the Labour government has done, this is the one that has done the most political damage, and it continues to do so. Some U-turns can get you back on the right road. Cartoon: Boris's comeback trial A busy week on the podcast interview front… Jacinda Ardern, Ed Miliband, and Arab Barghouthi. I'm guessing you've all recognised the first of those two names – Jacinda the former New Zealand prime minister, who is about to publish her highly emotional autobiography (spoiler alert, I really like it, but I'm biased, because I really like her); and Ed the former Labour minister and former Labour leader who lost an election but stayed around in frontline politics and is now the Cabinet minister charged with stopping the planet burning to death. The third name, I suspect, may be less familiar to you. Arab Barghouti knows that we interviewed him not because of who he is, but because of who his father is. So why not interview the father instead, you wonder? The answer is that Marwan Barghouthi has been in an Israeli jail for more than 20 years, and just as it's impossible for us to get into Gaza right now, ditto the jail where our interviewee's dad has spent much of his time in solitary confinement. He too may not be familiar to all of our readers. But in the Middle East Marwan Barghouthi is a household name, to many a hero, and to some – including Israeli politicians more moderate than those driving the current government – the man who could and should be the leader of the Palestinian people. As the horror and brutality of the Hamas attacks of October 7 unfolded, Rory Stewart and I decided that we should use the Rest Is Politics platform to try to explain the history of the conflict and the political complexities, and seek to be fair and balanced in our approach to all sides. We got plenty of plaudits for that effort, Rory's explainer of the history getting shared and viewed many millions of times, but also lots of flak; supporters of Israel sometimes felt we were apologists for terrorists, supporters of the Palestinians were more likely to suggest we were too soft on the Israeli government. But what started out as a fight between Israel and Hamas is now a fight by the government of Israel against the Palestinian people. What qualifies as genocide is a question for international law. However, that the far-right extremists in the Israeli government, led by Itamar Ben Gvir and Bezalel Smotrich, are acting with genocidal intent, can hardly be disputed; that intent is evident pretty much every time they open their mouths. One reason diplomats and politicians are attracted to the notion of President Marwan Barghouti is his lifelong commitment to a two-state solution which recognises Israel – he is fluent in Hebrew, which he learned in prison, and has built good relations with many Israeli politicians in the past – and his rejection of the taking of civilian life in the fight for the Palestinian cause. I strongly recommend you listen to Mr Barghouti Junior – the interview is out on our LEADING channel now – not just for the family story, but for his account of what life is really like for Palestinians in Gaza and the West Bank, and the suffering being deliberately inflicted upon them. I also urge the Israeli government media team to listen too, and understand that sometimes you can get your points across better by speaking softly, clearly and calmly, rather than just hammering pre-prepared talking points, and attacking the questioner when you don't like the question. Amid the bling, and the bung of a free Boeing 747, and the billion-dollar business deals, there was a lot of substance in Donald Trump's tour of the Gulf. That impression was perhaps reinforced by my new Trump-consumption tactic – I read rather than watch his speeches. The stomach churns a little less when you are not confronted by the whole monstrous picture. Strip away the usual BS and bluster, and his big speech in Riyadh was interesting, well-argued, and with a lot of food for thought. The historic stand-out moment from the trip, à mon avis, was his meeting with President Ahmed al-Sharaa, and his announcement that sanctions were to be lifted on Syria. Just three months ago (with apologies for another podcast plug, but it is relevant), we interviewed al-Sharaa, and though it was clear getting sanctions lifted was his big goal, he had little expectation that it would happen any time soon. And here we are, it's done, cue dancing in the streets of Damascus. The same people who have been giving me and Rory Stewart grief for being too hard (sic) on Israel were livid that we travelled to Syria to talk to al-Sharaa. Yet Trump lifts sanctions, praises to the skies a man who not long ago had a 'Most Wanted' multi-million bounty on his head, tells him how strong and handsome he is to boot, and largely pulls it off without opprobrium. Trump is nothing if not unpredictable, if I may mangle a mouthful of negatives. This particular piece of unpredictability strikes me as a risk worth taking. I'm not a big fan of awards ceremonies – black tie, usually too long, often cringe acceptance speeches – but I always make an exception for the Sport Industry Awards. I have been a judge, which gave me a great insight into the scope, scale – and impact – of the industry, and all it contributes to the UK. At this year's awards I presented the Integrity and Impact Award to a wonderful man named Mel Young, a homelessness campaigner. In his acceptance speech, Mel, a soft-spoken Scot, summed up his approach to life by saying that just because you can't do everything, you mustn't do nothing… you do something. His something was founding the Homeless World Cup in 2003, since when more than 100,000 homeless youngsters, across 74 countries and 450 cities, have been given the chance to take part in an international sports tournament. That of itself does not put a roof over their heads. But it gives them a chance, and plenty have seized it. The Lifetime Achievement Award went to boxing promoter Frank Warren and the Outstanding Contribution Award to cyclist Sarah Storey. She has won 19 Paralympic gold medals, and if she stays fit Los Angeles 2028 will be her TENTH Paralympics. Given the general British hopelessness at learning foreign languages, it was good to hear her explain how she won that last medal in Paris. She was up against a 'young French wonderkid,' and as they chased each other around the track, she could hear her rival's coach bellowing out tactical instructions. Doubtless the Frenchman assumed that Sarah was just your average Brit who didn't bother with other languages, because English is King. Little did he know!
Yahoo
14-05-2025
- Business
- Yahoo
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments
Cash Position: Ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, up from $132 million at year-end 2024. ATM Facility: Raised $35 million net in Q1 2025, with an additional $16 million since April 1. Credit Facility: Entered into a $100 million credit facility with Hercules Capital, with $15 million funding at closing and additional tranches available. R&D Expenses: $15.8 million for Q1 2025, down from $21.5 million in Q1 2024. G&A Expenses: $6 million for Q1 2025, up from $5.3 million in Q1 2024. Net Loss: $19.6 million or $0.26 per share for Q1 2025, compared to $24.4 million or $0.34 per share in Q1 2024. Warning! GuruFocus has detected 3 Warning Signs with ALT. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Altimmune Inc (NASDAQ:ALT) is optimistic about the upcoming readout of their IMPACT Phase 2b NASH trial, expecting to achieve key efficacy and safety objectives. The company has entered into a $100 million credit facility with Hercules Capital, enhancing financial flexibility for the development of pemvidutide. Altimmune Inc (NASDAQ:ALT) is expanding its clinical trials to include alcohol use disorder (AUD) and alcohol liver disease (ALD), addressing significant unmet medical needs. The company reported a strong cash position, ending the first quarter with $150 million in cash, cash equivalents, and short-term investments. Altimmune Inc (NASDAQ:ALT) is preparing for a Phase 3 trial in NASH, with plans to hold an end of Phase 2 meeting with the FDA in the fourth quarter of 2025. The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements. R&D expenses decreased from $21.5 million in Q1 2024 to $15.8 million in Q1 2025, which might indicate reduced investment in research and development. Net loss for the first quarter of 2025 was $19.6 million, indicating ongoing financial challenges. The company is still in the process of rereading biopsies for the IMPACT trial, which could affect the timeline and outcomes. There is uncertainty regarding the placebo response rate in the IMPACT trial, which could impact the trial's success. Q: Can you provide commentary on the distribution of F2 and F3 in the Phase 2b population and how representative it is compared to other successful Phase 2b studies? A: We are in the final stages of rereading the biopsies, so we can't provide precise numbers yet. However, the demographics, including age, sex, F2/F3 distribution, and other characteristics, are very similar to other studies, making our data meaningful and comparable. - Scott Harris, Chief Medical Officer Q: What is the ideal patient population for pemvidutide in MASH, and are there any partnership opportunities being considered? A: We are targeting MASH with obesity, as 80-90% of MASH patients are obese. Pemvidutide addresses both obesity and liver fibrosis, offering a comprehensive treatment. Regarding partnerships, we are open to discussions but are prepared to move forward with Phase 3 development independently. - Vipin Garg, Chief Executive Officer Q: How are discontinuations being handled in the study, and what is the expected placebo response range? A: Discontinuations are being managed well, and we are pleased with the data so far. Placebo responses have varied widely in past trials, but with our methodology, we expect to see a placebo response rate between 7% and 13%. - Scott Harris, Chief Medical Officer Q: How important is weight loss in the study, and what weight loss should be expected compared to semaglutide? A: Weight loss is crucial, especially for patients with obesity and cardiovascular risks. We expect clinically significant weight loss similar to semaglutide, which showed about 10% weight loss at 72 weeks. Our 24-week results should be comparable, providing a complete solution for MASH. - Scott Harris, Chief Medical Officer Q: What are the plans for Phase 3, and how might the development timeline be shortened? A: We are considering using a higher dose in Phase 3 for better weight loss and potentially having a six-month endpoint to accelerate the timeline. We plan to discuss these options with the FDA in the fourth quarter. - Scott Harris, Chief Medical Officer For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
